Monoclonal antibody therapy of chronic lymphocytic leukemia

@article{Cheson2005MonoclonalAT,
  title={Monoclonal antibody therapy of chronic lymphocytic leukemia},
  author={Bruce D Cheson},
  journal={Cancer Immunology, Immunotherapy},
  year={2005},
  volume={55},
  pages={188-196}
}
Cure of patients with chronic lymphocytic leukemia (CLL) has been an elusive goal. The recent availability of active monoclonal antibodies has rekindled enthusiasm for new and innovative therapeutic approaches. Alemtuzumab, induces responses in about a third of patients with relapsed or refractory CLL following therapy with fludarabine and an alkylating agent. Whereas, rituximab has limited activity in previously treated patients, response rates of 50–70% have been reported in those without… CONTINUE READING
2 Citations
93 References
Similar Papers

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 93 references

Efficacy and safety of alemtuzumab (CAMPATH-1H) in refractory B-CLL patients treated on a compassionate basis. Blood 98:365a (abstr

  • KR Rai, S Coutré, D Rizzieri
  • 2001
Highly Influential
5 Excerpts

Similar Papers

Loading similar papers…